Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

DNLI stock hub

Denali Therapeutics Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

DNLIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

DNLI

In the news

Latest news · DNLI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-49.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-698

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All DNLI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001714899
Company name	Denali Therapeutics Inc.
Country	United States
Country code	US
Cusip	24823R105
Employees	503
Employees Change	81%
Employees Change Percent	19.19
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-12-08
Isin	US24823R1059
Last refreshed	2026-05-10
Market cap	$3.1B
Market cap category	Mid-Cap
Price	$19.62
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	DNLI
Website	https://www.denalitherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-16.32%
EV Sales Forward	66.44x
FCF yield	-13.47%
P/B ratio	3.36x
PS Forward	98.88x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-418.8M
Net Income	$-508M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1M
ROA	-26.95
Roa5y	-17.79
ROCE	-47.33
ROE	-49.59
Roe5y	-31.43
ROIC	-698

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	37.04%
Cagr3y	-9.55%
Cagr5y	-18.42%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$1.3B
Cash	$987.7M
Current Assets	$1B
Current Liabilities	$110.2M
Debt	$30.2M
Debt Equity	$0.03
Equity	$926.1M
Liabilities	$339.9M
Long Term Assets	$243.3M
Long Term Liabilities	$229.8M
Net Cash	$1B
Net Cash By Market Cap	$32.8
Net Cash Growth	1.9%
Net Debt Equity	$-1.1
Tangible Book Value	$890.1M
Tangible Book Value Per Share	$5.61
WACC	9.63

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.28
Net Working Capital	$-75.1M
Quick ratio	8.97
Working Capital	$912.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.87%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	37.01%
200-day SMA	17.58
3Y total return	-26.02%
50-day SMA	20.03
50-day SMA vs 200-day SMA	50over200
5Y total return	-63.87%
All Time High	93.94
All Time High Change	-79.11%
All Time High Date	2020-12-22
All Time Low	10.57
All Time Low Change	85.62%
All Time Low Date	2025-04-07
ATR	1.05
Beta	0.99
Beta1y	0.96
Beta2y	1.87
Ch YTD	18.84
High	20.53
High52	23.77
High52 Date	2026-02-03
High52ch	-17.46%
Low	19.44
Low52	12.58
Low52 Date	2025-09-22
Low52ch	55.96%
Ma50ch	-2.05%
Premarket Change Percent	1.47
Premarket Price	$20
Premarket Volume	3,991
Price vs 200-day SMA	11.63%
RSI	49.55
RSI Monthly	49.64
RSI Weekly	52.82
Sharpe ratio	0.77x
Sortino ratio	1.31
Total Return	-3.87%
Tr YTD	18.84
Tr1m	1.08%
Tr1w	7.21%
Tr3m	-6.93%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	13
Analyst Count Top	7
Analyst Price Target Top	$32
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.71
Earnings Revenue Estimate	3,817,848x
Operating Income	$-547.1M
Price target	$33.91
Price Target Change	$72.83
Price Target Change Top	$63.1

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	144,239,769%
Float Percent	90.9%
Net Borrowing	-3,828,000
Shares Insiders	4.59%
Shares Institutions	98.29%
Shares Out	158,675,498
Shares Qo Q	6.37%
Shares Yo Y	3.87%
Short Float	10.6%
Short Ratio	7.98
Short Shares	9.63

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-516.8M
Average Volume	1,609,706x
Bv Per Share	5.84
CAPEX	$-6.9M
Ch1m	1.08
Ch1w	7.21
Ch1y	37.01
Ch3m	-6.93
Ch3y	-26.02
Ch5y	-63.87
Ch6m	30.63
Change	-0.46%
Change From Open	0.93
Close	19.71
Days Gap	-1.37
Depreciation Amortization	15,361,000
Dollar Volume	38,176,792.2
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-547.1M
EBITDA	$-531.8M
EPS	$-2.88
F Score	1
FCF	$-419.2M
FCF EV Yield	-20.04x
FCF Per Share	$-2.64
Financing CF	412,022,000
Fiscal Year End	December
Founded	2,013
Income Tax	$102,000
Investing CF	330,993,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	18.65
Ma150ch	5.22%
Ma20	19.79
Ma20ch	-0.84%
Net CF	330,679,000
Next Earnings Date	2026-08-10
Open	19.44
Optionable	Yes
Position In Range	16.51
Post Close	19.62
Postmarket Change Percent	-0.78
Postmarket Price	$19.47
Ppne	117,266,000
Pre Close	19.71
Price Date	2026-05-08
Ptbv Ratio	3.5
Relative Volume	1.21x
Share Based Comp	97,560,000
Tr6m	30.63%
Us State	California
Volume	1,945,810

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does DNLI pay a dividend?

Capital-return profile for this ticker.

Performance

DNLI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns DNLI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+98.3%

Float: +90.9% of shares outstanding

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

DNLI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

49.5

Neutral momentum band

Price vs 200-day MA

+11.6%

50/200-day relationship not available

Beta (5Y)

0.99

Moves roughly with the market

Sharpe ratio

0.77

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About DNLI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current DNLI stock rating?

Denali Therapeutics Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DNLI analysis?

The full report lives at /stocks/DNLI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for DNLI?

The latest report frames DNLI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the DNLI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.